Literature DB >> 22155678

Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: a Gynecologic Oncology Group study.

Krishnansu S Tewari1, Virginia L Filiaci, Nick M Spirtos, Robert S Mannel, J Tate Thigpen, Michael L Cibull, Bradley J Monk, Marcus E Randall.   

Abstract

OBJECTIVE: To determine whether the number of positive pelvic nodes (PPN), cervical stromal involvement (CSI), and/or lymphovascular space involvement (LVSI) were prognostic factors among women with advanced endometrial carcinoma treated with adriamycin plus cisplatin (AP) or whole abdominal irradiation (WAI).
METHODS: Data were abstracted from records of patients treated with adjuvant WAI or AP in a GOG randomized trial. Cox proportional hazards models were used to estimate the association of CSI and PPN with differences in PFS and OS while adjusting for treatment and previously studied factors.
RESULTS: WAI was randomly allocated to 202 and AP to 194 eligible patients. CSI (n=93 total) was associated with a 44% increase in risk of progression and a 33% increase in risk of death. There was a trend for increasing number PPN being associated with a 7% per positive node increase in risk of progression/death. For CSI, the estimated unadjusted treatment hazard ratios (HRs) were: PFS 0.85 (0.53, 1.38); OS 0.81 (0.50, 1.33). For metastatic disease limited to a single PPN (n=25), the unadjusted HRs were: PFS 0.96 (0.34, 2.74); OS 0.73 (0.24, 2.18). The test of homogeneity of treatment effect (ie., AP vs WAI) across subgroups (CSI, number of positive pelvic nodes) was not statistically significant for either endpoint, thus supporting the superiority of chemotherapy as reported in the original manuscript.
CONCLUSIONS: The presence of CSI and increasing number of PPN were associated with poor prognosis. On average, patients with CSI experienced improved PFS and OS when treated with AP relative to WAI. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155678     DOI: 10.1016/j.ygyno.2011.12.414

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  11 in total

1.  Histologic grade and peritoneal cytology as prognostic factors in type 1 endometrial cancer.

Authors:  Kei Tanaka; Yoichi Kobayashi; Juri Sugiyama; Tatsuo Yamazaki; Kei Dozono; Momoe Watanabe; Hiromi Shibuya; Yoshiko Nishigaya; Mai Momomura; Hironori Matsumoto; Satoshi Umezawa; Kiyoshi Takamatsu; Mitsutoshi Iwashita
Journal:  Int J Clin Oncol       Date:  2017-01-12       Impact factor: 3.402

2.  Endometrial cancer with cervical stromal invasion: diagnostic accuracy of diffusion-weighted and dynamic contrast enhanced MR imaging at 3T.

Authors:  Gigin Lin; Yu-Ting Huang; Angel Chao; Yu-Chun Lin; Lan-Yan Yang; Ren-Chin Wu; Hsin-Ying Lu; Shu-Hang Ng; Koon-Kwan Ng; Chyong-Huey Lai
Journal:  Eur Radiol       Date:  2016-09-09       Impact factor: 5.315

Review 3.  Fertility-sparing for young patients with gynecologic cancer: How MRI can guide patient selection prior to conservative management.

Authors:  Sinead H McEvoy; Stephanie Nougaret; Nadeem R Abu-Rustum; Hebert Alberto Vargas; Elizabeth A Sadowski; Christine O Menias; Fuki Shitano; Shinya Fujii; Ramon E Sosa; Joanna G Escalon; Evis Sala; Yulia Lakhman
Journal:  Abdom Radiol (NY)       Date:  2017-10

4.  Sentinel Lymph Node Mapping in Patients with Endometrial Carcinoma: Less Can Be More.

Authors:  Mario M Leitao
Journal:  Curr Obstet Gynecol Rep       Date:  2016-10-03

5.  High-risk endometrial cancer may be benefit from adjuvant radiotherapy plus chemotherapy.

Authors:  Jin-Wei Miao; Xiao-Hong Deng
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

6.  Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy.

Authors:  Mario M Leitao; Qin C Zhou; Natalia R Gomez-Hidalgo; Alexia Iasonos; Ray Baser; Marissa Mezzancello; Kaity Chang; Jae Ward; Dennis S Chi; Kara Long Roche; Yukio Sonoda; Carol L Brown; Jennifer J Mueller; Ginger J Gardner; Elizabeth L Jewell; Vance Broach; Oliver Zivanovic; Sean C Dowdy; Andrea Mariani; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2019-11-25       Impact factor: 5.482

7.  The survival outcome and patterns of failure in node positive endometrial cancer patients treated with surgery and adjuvant radiotherapy with curative intent.

Authors:  Chrishanthi Rajasooriyar; David Bernshaw; Srinivas Kondalsamy-Chennakesavan; Linda Mileshkin; Kailash Narayan
Journal:  J Gynecol Oncol       Date:  2014-08-05       Impact factor: 4.401

8.  Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer.

Authors:  Mauro Signorelli; Andrea Alberto Lissoni; Elena De Ponti; Tommaso Grassi; Serena Ponti; Robert Fruscio
Journal:  J Gynecol Oncol       Date:  2015-07-14       Impact factor: 4.401

9.  Survival and recurrence in stage II endometrial cancers in relation to uterine risk stratification after introduction of lymph node resection and omission of postoperative radiotherapy: a Danish Gynecological Cancer Group Study.

Authors:  Gitte Ørtoft; Claus Høgdall; Estrid S Hansen; Margit Dueholm
Journal:  J Gynecol Oncol       Date:  2019-10-04       Impact factor: 4.401

Review 10.  Adjuvant chemotherapy for advanced endometrial cancer.

Authors:  Khadra Galaal; Mansour Al Moundhri; Andrew Bryant; Alberto D Lopes; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2014-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.